Search Results

There are 2287 results for: content related to: Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting

  1. You have full text access to this Open Access content
    Multicenter, phase II, placebo-controlled, double-blind, randomized study of aprepitant in Japanese patients receiving high-dose cisplatin

    Cancer Science

    Volume 101, Issue 11, November 2010, Pages: 2455–2461, Toshiaki Takahashi, Eishin Hoshi, Masakazu Takagi, Noriyuki Katsumata, Masaaki Kawahara and Kenji Eguchi

    Version of Record online : 24 JUL 2010, DOI: 10.1111/j.1349-7006.2010.01689.x

  2. You have free access to this content
    Guideline for the prevention of acute nausea and vomiting due to antineoplastic medication in pediatric cancer patients

    Pediatric Blood & Cancer

    Volume 60, Issue 7, July 2013, Pages: 1073–1082, L. Lee Dupuis, Sabrina Boodhan, Mark Holdsworth, Paula D. Robinson, Richard Hain, Carol Portwine, Erin O'Shaughnessy and Lillian Sung

    Version of Record online : 19 MAR 2013, DOI: 10.1002/pbc.24508

  3. Economic analysis of aprepitant-containing regimen to prevent chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy in Hong Kong

    Asia-Pacific Journal of Clinical Oncology

    Volume 10, Issue 1, March 2014, Pages: 80–91, Stephen L Chan, Jason Jen, Thomas Burke and James Pellissier

    Version of Record online : 20 FEB 2014, DOI: 10.1111/ajco.12170

  4. Development of aprepitant, the first neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting

    Annals of the New York Academy of Sciences

    Volume 1222, Issue 1, March 2011, Pages: 40–48, Richard Hargreaves, Juan Camilo Arjona Ferreira, David Hughes, Jos Brands, Jeff Hale, Britta Mattson and Sandy Mills

    Version of Record online : 22 MAR 2011, DOI: 10.1111/j.1749-6632.2011.05961.x

  5. Pharmacokinetics of Oral Dexamethasone and Midazolam When Administered With Single-Dose Intravenous 150 mg Fosaprepitant in Healthy Adult Subjects

    The Journal of Clinical Pharmacology

    Volume 51, Issue 12, December 2011, Pages: 1712–1720, Dr Thomas C. Marbury, Ms Phung L. Ngo, Mr Craig R. Shadle, Dr Bo Jin, Ms Deborah Panebianco, Dr Luzelena Caro, Dr Jack Valentine and Dr Gail Murphy

    Version of Record online : 12 MAR 2013, DOI: 10.1177/0091270010387792

  6. Equivalent Dynamic Human Brain NK1-Receptor Occupancy Following Single-Dose i.v. Fosaprepitant vs. Oral Aprepitant as Assessed by PET Imaging

    Clinical Pharmacology & Therapeutics

    Volume 92, Issue 2, August 2012, Pages: 243–250, K Van Laere, J De Hoon, G Bormans, M Koole, I Derdelinckx, I De Lepeleire, R Declercq, S M Sanabria Bohorquez, T Hamill, P D Mozley, D Tatosian, W Xie, Y Liu, F Liu, P Zappacosta, C Mahon, K L Butterfield, L B Rosen, M G Murphy, R J Hargreaves, J A Wagner and C R Shadle

    Version of Record online : 27 JUN 2012, DOI: 10.1038/clpt.2012.62

  7. Pharmacokinetics of Aprepitant After Single and Multiple Oral Doses in Healthy Volunteers

    The Journal of Clinical Pharmacology

    Volume 46, Issue 3, March 2006, Pages: 291–300, Dr Anup K. Majumdar, Ms Laura Howard, Dr Michael R. Goldberg, Ms Lisa Hickey, Mr Marvin Constanzer, Dr Paul L. Rothenberg, Ms Tami M. Crumley, Ms Deborah Panebianco, Dr Thomas E. Bradstreet, Dr Arthur J. Bergman, Dr Scott A. Waldman, Dr Howard E. Greenberg, Dr Kathleen Butler, Dr A. Knops, Dr Inge De Lepeleire, Ms Nicole Michiels and Dr Kevin J. Petty

    Version of Record online : 8 MAR 2013, DOI: 10.1177/0091270005283467

  8. You have free access to this content
    Antiemetic efficacy of the neurokinin-1 antagonist, aprepitant, plus a 5HT3 antagonist and a corticosteroid in patients receiving anthracyclines or cyclophosphamide in addition to high-dose cisplatin

    Cancer

    Volume 104, Issue 4, 15 August 2005, Pages: 864–868, Richard J. Gralla, Ronald de Wit, Jorn Herrstedt, Alexandra D. Carides, Juliana Ianus, Julie Guoguang-Ma, Judith K. Evans and Kevin J. Horgan

    Version of Record online : 22 JUN 2005, DOI: 10.1002/cncr.21222

  9. You have free access to this content
    Cost-Effectiveness of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting Associated with Highly Emetogenic Chemotherapy

    Value in Health

    Volume 10, Issue 1, January/February 2007, Pages: 23–31, Susan Moore, John Tumeh, Steven Wojtanowski and Christopher Flowers

    Version of Record online : 22 NOV 2006, DOI: 10.1111/j.1524-4733.2006.00141.x

  10. Aprepitant in pediatric patients using moderate and highly emetogenic protocols: a systematic review and meta-analyses of randomized controlled trials

    British Journal of Clinical Pharmacology

    Lucas Miyake Okumura, Fernanda D'Athayde Rodrigues, Maria Angelica Pires Ferreira and Leila Beltrami Moreira

    Version of Record online : 12 JAN 2017, DOI: 10.1111/bcp.13193

  11. A Single-Dose Bioequivalence and Food Effect Study With Aprepitant and Fosaprepitant Dimeglumine in Healthy Young Adult Subjects

    Clinical Pharmacology in Drug Development

    Volume 1, Issue 3, July 2012, Pages: 93–101, Craig R. Shadle, M. Gail Murphy, Yang Liu, Maureen Ho, Daniel Tatosian, Susie (Xiujiang) Li and Robert A. Blum

    Version of Record online : 10 JAN 2013, DOI: 10.1177/2160763X12447304

  12. You have free access to this content
    Guideline for the Treatment of Breakthrough and the Prevention of Refractory Chemotherapy-Induced Nausea and Vomiting in Children With Cancer

    Pediatric Blood & Cancer

    Volume 63, Issue 7, July 2016, Pages: 1144–1151, Jacqueline Flank, Paula D. Robinson, Mark Holdsworth, Robert Phillips, Carol Portwine, Paul Gibson, Cathy Maan, Nancy Stefin, Lillian Sung and L. Lee Dupuis

    Version of Record online : 9 MAR 2016, DOI: 10.1002/pbc.25955

  13. You have free access to this content
    Palonosetron with aprepitant plus dexamethasone to prevent chemotherapy-induced nausea and vomiting during gemcitabine/cisplatin in urothelial cancer patients

    International Journal of Urology

    Volume 22, Issue 10, October 2015, Pages: 911–914, Hiroshi Kitamura, Atsushi Takahashi, Hiroshi Hotta, Ryuichi Kato, Yasuharu Kunishima, Fumiyasu Takei, Hiroki Horita, Naoya Masumori and on behalf of the Sapporo Medical University Urologic Oncology Consortium

    Version of Record online : 18 JUN 2015, DOI: 10.1111/iju.12842

  14. You have free access to this content
    Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting

    Cancer

    Volume 97, Issue 9, 1 May 2003, Pages: 2290–2300, Sant P. Chawla, Steven M. Grunberg, Richard J. Gralla, Paul J. Hesketh, Cindy Rittenberg, Mary E. Elmer, Carrie Schmidt, Arlene Taylor, Alexandra D. Carides, Judith K. Evans and Kevin J. Horgan

    Version of Record online : 17 APR 2003, DOI: 10.1002/cncr.11320

  15. You have full text access to this OnlineOpen article
    Combination of aprepitant, palonosetron and dexamethasone as antiemetic prophylaxis in lung cancer patients receiving multiple cycles of cisplatin-based chemotherapy

    International Journal of Clinical Practice

    Volume 66, Issue 8, August 2012, Pages: 753–757, F. Longo, G. Mansueto, V. Lapadula, L. Stumbo, G. Del Bene, D. Adua, L. De Filippis, E. Bonizzoni and S. Quadrini

    Version of Record online : 2 JUL 2012, DOI: 10.1111/j.1742-1241.2012.02969.x

  16. Evaluation of Potential Inductive Effects of Aprepitant on Cytochrome P450 3A4 and 2C9 Activity

    The Journal of Clinical Pharmacology

    Volume 44, Issue 3, March 2004, Pages: 215–223, Mr Craig R. Shadle, Dr Yih Lee, Dr Anup K. Majumdar, Dr Kevin J. Petty, Ms Cynthia Gargano, Dr Thomas E. Bradstreet, Dr Judith K. Evans and Dr Robert A. Blum

    Version of Record online : 8 MAR 2013, DOI: 10.1177/0091270003262950

  17. Aprepitant for the control of chemotherapy induced nausea and vomiting in adolescents

    Pediatric Blood & Cancer

    Volume 45, Issue 6, November 2005, Pages: 857–860, Angela R. Smith, Tanya L. Repka and Brenda J. Weigel

    Version of Record online : 24 APR 2005, DOI: 10.1002/pbc.20378

  18. Lack of Effect of Aprepitant on Hydrodolasetron Pharmacokinetics in CYP2D6 Extensive and Poor Metabolizers

    The Journal of Clinical Pharmacology

    Volume 46, Issue 7, July 2006, Pages: 792–801, Dr Susie Xiujiang Li, Mr Edward Pequignot, Ms Deborah Panebianco, Dr Paul Lupinacci, Dr Anup Majumdar, Dr Laura Rosen, Ms Tuli Ahmed, Dr Jane E. Royalty, Dr Thomas H. Rushmore, Dr M. Gail Murphy and Dr Kevin J. Petty

    Version of Record online : 8 MAR 2013, DOI: 10.1177/0091270006288954

  19. Efficacy of aprepitant in management of chemotherapy-induced nausea and vomiting

    Internal Medicine Journal

    Volume 37, Issue 4, April 2007, Pages: 247–250, J. A. A. Osorio-Sanchez, C. Karapetis and B. Koczwara

    Version of Record online : 27 MAR 2007, DOI: 10.1111/j.1445-5994.2007.01311.x

  20. Aprepitant in antiemetic combinations to prevent chemotherapy-induced nausea and vomiting

    International Journal of Clinical Practice

    Volume 58, Issue 2, February 2004, Pages: 201–206, I.N. Olver

    Version of Record online : 8 MAR 2004, DOI: 10.1111/j.1368-5031.2004.0135.x